Literature DB >> 23230963

Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.

Zhen-Dong Shi1, Xiao-Min Qian, Chao-Yong Liu, Lei Han, Kai-Liang Zhang, Lu-Yue Chen, Jun-Xia Zhang, Pei-Yu Pu, Xu-Bo Yuan, Chun-Sheng Kang.   

Abstract

BACKGROUND AND AIMS: Currently temozolomide (TMZ) as a potent agent is widely used to treat the glioblastoma multiforme (GBM), whereas recurrence due to intrinsic or acquired therapeutic resistance often occurs. Combination chemotherapy with TMZ may be a promising therapeutic strategy to improve treatment efficacy.
METHODS: Aspirin, TMZ, and aspirin-/TMZ-coloaded poly (L-lactide-co-glycolide) (PLGA) microspheres were prepared by spray drying, and cytotoxicities of glioblastoma cells were measured.
RESULTS: Aspirin microsphere treatment induced slight apoptosis and modestly inhibited proliferation of LN229 and U87 cells in vitro and in vivo through inhibition of β-catenin transactivation. However, aspirin-/TMZ-coloaded microspheres presented synergistic antitumor efficacy compared with single TMZ-loaded microspheres. Aspirin/TMZ microspheres induced more apoptosis and repressed proliferation of LN229 and U87 cells. Corresponding to inhibition of β-catenin signaling, β-catenin/TCF4 transcriptional activity and STAT3 luciferase activity were strongly suppressed, and downstream targets expression was decreased. Furthermore, aspirin/TMZ microsphere intratumoral injection downregulated the expression of β-catenin, TCF4, pAKT, pSTAT3, and PCNA and delayed tumor growth in nude mice harboring subcutaneous LN229 xenografts.
CONCLUSIONS: Aspirin sensitized TMZ chemotherapy efficacy through inhibition of β-catenin transactivation; furthermore, the coloaded microspheres achieved a sustained release action to reduce the TMZ dosage, offering the potential for improved treatment of glioblastomas.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23230963      PMCID: PMC6694282          DOI: 10.1111/cns.12041

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  41 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  About the evaluation of drug combination.

Authors:  Zheng-jun Jin
Journal:  Acta Pharmacol Sin       Date:  2004-02       Impact factor: 6.150

3.  Stat3 regulates genes common to both wound healing and cancer.

Authors:  Daniel J Dauer; Bernadette Ferraro; Lanxi Song; Bin Yu; Linda Mora; Ralf Buettner; Steve Enkemann; Richard Jove; Eric B Haura
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

Review 4.  Synthesis and characterization of PLGA nanoparticles.

Authors:  Carlos E Astete; Cristina M Sabliov
Journal:  J Biomater Sci Polym Ed       Date:  2006       Impact factor: 3.517

Review 5.  Targeting multiple arms of the apoptotic regulatory machinery.

Authors:  Yun Dai; Steven Grant
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

Authors:  Raja B Khan; Jeffrey J Raizer; Mark G Malkin; Kimberley A Bazylewicz; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2002-01       Impact factor: 12.300

7.  Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 8.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.

Authors:  Simona Caporali; Lauretta Levati; Giuseppe Starace; Gianluca Ragone; Enzo Bonmassar; Ester Alvino; Stefania D'Atri
Journal:  Mol Pharmacol       Date:  2008-04-15       Impact factor: 4.436

Review 10.  Mechanisms of disease: temozolomide and glioblastoma--look to the future.

Authors:  Maciej M Mrugala; Marc C Chamberlain
Journal:  Nat Clin Pract Oncol       Date:  2008-06-10
View more
  8 in total

1.  The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Authors:  Lauren E Bartels; George Mattheolabakis; Brandon M Vaeth; Joseph F LaComb; Ruixue Wang; Jizu Zhi; Despina Komninou; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2016-02-10       Impact factor: 4.944

2.  AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.

Authors:  Lei Han; Kai-Liang Zhang; Jun-Xia Zhang; Liang Zeng; Chun-Hui Di; Brian E Fee; Miriam Rivas; Zhao-Shi Bao; Tao Jiang; Darrell Bigner; Chun-Sheng Kang; David Cory Adamson
Journal:  CNS Neurosci Ther       Date:  2014-02-01       Impact factor: 5.243

3.  HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways.

Authors:  Ran Duan; Lei Han; Qixue Wang; Jianwei Wei; Luyue Chen; Jianning Zhang; Chunsheng Kang; Lei Wang
Journal:  Oncotarget       Date:  2015-09-29

4.  Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.

Authors:  Jianguang Ming; Bo Sun; Ziwei Li; Lin Lin; Xiangqi Meng; Bo Han; Ruijia Wang; Pengfei Wu; Jianlong Li; Jinquan Cai; Chuanlu Jiang
Journal:  Aging (Albany NY)       Date:  2017-04       Impact factor: 5.682

5.  Survival as a Function of Nonsteroidal Anti-inflammatory Drug Use in Patients with Glioblastoma.

Authors:  Ryan P Bruhns; Whitney S James; Mohammad Torabi; Mark Borgstrom; Adam Roussas; Michael Lemole
Journal:  Cureus       Date:  2018-09-10

Review 6.  Nanocarrier-based drug combination therapy for glioblastoma.

Authors:  Mengnan Zhao; Demian van Straten; Marike L D Broekman; Véronique Préat; Raymond M Schiffelers
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 7.  Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment.

Authors:  Lin Tang; Yicheng Feng; Sai Gao; Qingchun Mu; Chaoyong Liu
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

8.  Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.

Authors:  Q Wei; Z Ye; X Zhong; L Li; C Wang; R E Myers; J P Palazzo; D Fortuna; A Yan; S A Waldman; X Chen; J A Posey; A Basu-Mallick; B H Jiang; L Hou; J Shu; Y Sun; J Xing; B Li; H Yang
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.